Impact of Perioperative Multimodal Blood Management of Bone Tumors of Hip on Early Postoperative Functional Recovery: A Retrospective Cohort Study

Background This study evaluated the efficacy of a perioperative multimodal blood management strategy—combining erythropoietin, iron supplementation, and restrictive transfusion protocols—in patients undergoing surgery for hip bone tumors, to optimize their perioperative care. Methods We conducted a retrospective analysis of 38 patients who underwent hip bone tumor surgery between January 2021 and February 2025. Based on inclusion and exclusion criteria, patients were divided into a control group (n = 24) and a multimodal management group (n = 14). We compared baseline characteristics, preoperative laboratory results, surgical and postoperative data, dynamic hemoglobin changes, FACIT-Fatigue scores, and Harris Hip Scores between the groups. Results Preoperative hemoglobin was lower and surgical duration was longer in the multimodal management group compared to the controls (both p < 0.05). At one month postoperatively, the multimodal group demonstrated significantly greater improvement in both FACIT-Fatigue scores (5.79 ± 2.01 vs. 3.00 ± 0.78, p < 0.05) and Harris Hip Scores (30.57 ± 6.03 vs. 25.25 ± 6.46, p < 0.05). By three months postoperatively, scores between the two groups were comparable (p > 0.05). Conclusions Despite lower preoperative hemoglobin and more complex surgeries, the multimodal blood management strategy facilitated superior early functional recovery and accelerated rehabilitation at a critical postoperative time point.